
    
      In this trial, T cells are seperated from multiple myeloma patients, and engineered into
      BMCA-targeted CAR-T cells, these cells are then transfused back into the patients to
      elimimnate the myeloma cells. In this process, the safety and efficacy of this CAR-T
      treatment are closely monitored.
    
  